Scioto Biosciences Invested 2018

Scioto Biosciences is a preclinical stage company developing innovative therapies devoted to having a transformative impact on the delivery of microbiome therapeutics. The Scioto Platform is a novel formulation that primes the colony-forming mechanisms of live bacteria therapeutics by combining beneficial bacteria with polysaccharide microspheres. These natural mechanisms induce biofilm formation, enhance function and allow for non-spore forming bacteria to survive passage through the gastrointestinal system. The platform has the potential to enhance efficacy wherever live bacterial therapeutics are used such as diabetes, neurological disorders, gastrointestinal health, alternatives to in-feed antibiotics for livestock, and others.